## **DEPARTMENT OF JUSTICE**

## **Antitrust Division**

Notice Pursuant to the National Cooperative Research and Production Act of 1993—Network Centric Operations Industry Consortium, Inc.

Notice is hereby given that, on December 5, 2017, pursuant to Section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 et seq. ("the Act"), Network Centric Operations Industry Consortium, Inc. ("NCOIC") has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act's provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, Marc Fiammante (individual member), Alpes Maritimes, FRANCE, has been added as a party to this venture.

No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and NCOIC intends to file additional written notifications disclosing all changes in membership.

On November 19, 2004, NCOIC filed its original notification pursuant to Section 6(a) of the Act. The Department of Justice published a notice in the **Federal Register** pursuant to Section 6(b) of the Act on February 2, 2005 (70 FR 5486).

The last notification was filed with the Department on July 11, 2017. A notice was published in the **Federal Register** pursuant to Section 6(b) of the Act on August 15, 2017 (82 FR 38711).

## Patricia A. Brink,

Director of Civil Enforcement, Antitrust Division.

[FR Doc. 2017–28129 Filed 12–28–17; 8:45 am]  ${\tt BILLING}$  CODE P

## **DEPARTMENT OF JUSTICE**

## **Drug Enforcement Administration**

[Docket No. DEA-392]

Bulk Manufacturer of Controlled Substances Application: AMPAC Fine Chemicals LLC

**ACTION:** Notice of application.

**DATES:** Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written

comments on or objections to the issuance of the proposed registration on or before February 27, 2018.

ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DRW, 8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: The Attorney General has delegated his authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Assistant Administrator of the DEA Diversion Control Division ("Assistant Administrator'') pursuant to section 7 of 28 CFR part 0, appendix to subpart R.

In accordance with 21 CFR 1301.33(a), this is notice that on October 28, 2016, AMPAC Fine Chemicals Virginia, LLC, 2820 North Normandy Drive, Petersburg, Virginia 23805–2380 applied to be registered as a bulk manufacturer of the following basic classes of controlled substances:

Controlled substance	Drug code	Schedule
Methylphenidate	1724	
Levomethorphan	9210	
Levorphanol	9220	

The company plans to manufacture the listed controlled substances in bulk for distribution to its customers.

Dated: December 15, 2017.

# Demetra Ashley,

Acting Assistant Administrator.

[FR Doc. 2017–28178 Filed 12–28–17; 8:45 am]

BILLING CODE 4410–09–P

# **DEPARTMENT OF JUSTICE**

Drug Enforcement Administration [Docket No. DEA-392]

Importer of Controlled Substances
Application: ABBVIE LTD; Correction

**ACTION:** Notice; correction.

**SUMMARY:** The Drug Enforcement Administration (DEA) published a document in the **Federal Register** of December 1, 2017, concerning a notice

of application that inadvertently misstated what the firm plans to do with imported tapentadol.

### Correction

In the **Federal Register** of December 1, 2017, in FR Doc. 2017–25921 (82 FR 230), on page 230, in the second column, the last paragraph, correct the first sentence to read: The company plans to import bulk tapentadol (9780) to manufacture dosage form tapentadol (9780) for distribution to its customers.

### Demetra Ashley,

Acting Assistant Administrator. [FR Doc. 2017–28176 Filed 12–28–17; 8:45 am] BILLING CODE 4410–09–P

### **DEPARTMENT OF JUSTICE**

Drug Enforcement Administration [Docket No. DEA-392]

Bulk Manufacturer of Controlled Substances Application: Cambrex High Point, Inc.

**ACTION:** Notice of application.

**DATES:** Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before February 27, 2018.

ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DRW, 8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: The Attorney General has delegated his authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Assistant Administrator of the DEA Diversion Control Division ("Assistant Administrator") pursuant to section 7 of 28 CFR part 0, appendix to subpart R.

In accordance with 21 CFR
1301.33(a), this is notice that on
November 22, 2016, Cambrex High
Point, Inc., 4180 Mendenhall Oaks
Parkway, High Point, North Carolina
27265 applied to be registered as a bulk